| Tradename: | Tai'ai |
| Routes Of Administration: | Injection |
| Legal Status: | Rx in China |
| Cas Number: | 2136630-26-5 |
| Unii: | 1FHM3D7Z49 |
| Synonyms: | RC18 |
Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE).[1] It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases.[2] In 2021, telitacicept was approved in China for the treatment of patients with active SLE.[3] It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS).[3]
Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).[3]